Dr. Patrick Lu Speaks in “The European Smmit for Clinical Nanomedicine and Targeted Medicine”
“The 7th European Summit for Clinical Nanomedicine and Targeted Medicine” with a subtitle “ Paving the way to persionalized diagnosis and therapy” was held in Basel, Switzerland during June 23-25, 2014. This is an annual conference organized by European Foundation for Clinical Nanomedicine (CLINAM). Dr. Patrick Lu, President and CSO of Sirnaomics, Inc., was invited by the organizing committee to speak in a platinum session “Peptide-Based Nanoparticles for Targeted Delivery of siRNA”.
The conference brings together Clinical Nanomedicine and Targeted Medicine into the generic context with Personalized Medicine and offers the international debate on precise, highly effective novel medicine using Nanomedicine and Targeted Delivery for Diagnosis and Therapy, leading to individualized therapy. The translation process from research findings to applications in Nanomedicine and Targeted Medicine has gained significant momentum. The conference is pushing the borders of the state of art of nanotechnology at both drug delivery and molecular diagnosis fronts.
During the presentation, Dr. Lu first gave an overview of current development t of siRNA therapeutics regarding the clinical advances, industry partnerships and financial market dynamics, followed with introduction of Sirnaomics’ experience in applying their three generations of peptide-based polymeric nanopartices on siRNA deliveries for treatments of several critical human conditions, fibrotic scarring, influenza infection and cancers. Dr. Lu and his R&D team have developed a formulation process under cGMP standard for Histidine-Lysine Polymer (HKP) siRNA nanoparticles. The toxicity studies of those nanoparticle formulations with mouse and non-human primate models through local and systemic administrations showed no safety concerns. Taking advantage of this platform technology for siRNA delivery, they are developing the siRNA therapeutic programs for hypertrophic scar prevention and treatment (STP705), “Resistance-Proof” influenza therapeutics (STP702), and cancer therapeutics (STP503). Dr. Lu has also elaborated their efforts pushing the leading program STP705 to clinic in both China and USA.
Clearly, using peptide based delivery systems for novel siRNA therapeutic development is an ideal example how nanomedicine is becoming reality. Dr. Lu’s presentation has generated ample interests to the audience and also led to a series of partnership discussions.